UBS Group
WST icon

UBS Group’s West Pharmaceutical WST Stock Holding History

UBS Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.51M Hold
14,000
– – ﹤0.01% 4435
2025
Q4 		$3.85M Hold
14,000
– – ﹤0.01% 4298
2025
Q3 		$3.67M Buy
+14,000
New +$3.4M ﹤0.01% 4353
2015
Q1 		– Sell
-500
Closed -$27K – 9452
2014
Q4 		$27K Buy
+500
New +$25K ﹤0.01% 7234

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's WST Position: Q1 2026 in Review

UBS Group increased its West Pharmaceutical (WST) stake by 10% in Q1 2026, buying an estimated $6.25M and bringing the position to 275,508 shares worth $69.1M. The position accounts for 0.01% of the portfolio, ranked #1330.

UBS Group first reported a position in WST in Q4 2014 and has held it in 46 quarters since. The position peaked at $77.4M in Q3 2025. 754 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • UBS Group held 275,508 shares of West Pharmaceutical worth $69.1M as of Q1 2026.
  • UBS Group bought 25,110 West Pharmaceutical shares in Q1 2026, an estimated $6.25M.
  • West Pharmaceutical made up 0.01% of UBS Group's portfolio in Q1 2026, its #1330 holding.
  • UBS Group first reported a position in West Pharmaceutical in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's West Pharmaceutical position peaked at $77.4M in Q3 2025.
  • 754 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.